Patent Ductus Arteriosus Management and Outcomes in Japan and Canada: Comparison of Proactive and Selective Approaches

Abstract

Objective The aim of this study is to compare patent ductus arteriosus (PDA) management strategies and outcomes between the Neonatal Research Network of Japan (NRNJ) with proactive functional echocardiography and the Canadian Neonatal Network (CNN) with selective conventional echocardiography practice.

Study Design Retrospective analyses examined very low-birth-weight infants admitted to the NRNJ or CNN in 2006 to 2008. Multivariable logistic regression analyses compared a composite outcome indicating a mortality or major morbidity (severe intraventricular hemorrhage, periventricular leukomalacia, severe retinopathy of prematurity, bronchopulmonary dysplasia, or necrotizing enterocolitis) between networks, according to PDA diagnosis and treatment, and tested the association between PDA treatment and the composite outcome within networks.

Results PDA treatment (NRNJ:CNN) with conservative management (8%:16%), indomethacin only (77%:59%), ligation only (1%:13%), or indomethacin and ligation (14%:13%) varied significantly between networks. The composite outcome was lower in NRNJ versus CNN only among infants with PDA (odds ratio: 0.70; 95% confidence interval: 0.62–0.80). Surgical ligation was associated with higher composite outcome only in CNN (odds ratio: 1.79; 95% confidence interval: 1.40–2.28).

Conclusion Lower composite mortality/morbidity outcome in Japan versus Canada only among infants with PDA, and association of surgical ligation with higher mortality/morbidity only in Canada, suggest differential PDA management and ligation processes contribute to outcome variation.

Keywords

patent ductus arteriosus - premature infants - echocardiography - mortality - morbidities

• References

• 1 Noori S, McCoy M, Friedlich P , et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123 (1) e138-e144
• 2 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010; 30 (4) 241-252
• 3 Hoellering AB, Cooke L. The management of patent ductus arteriosus in Australia and New Zealand. J Paediatr Child Health 2009; 45 (4) 204-209
• 4 Toyoshima K. The management of circulation in acute phase of high-risk infants and quality improvement project in perinatal medicine [in Japanese]. In: Records of the 9th Annual Meeting of the Japanese Perinatal Circulation Management Study Group; 26–27 November 2011; Sendai, Japan. Available at: http://blogs.yahoo.co.jp/nicu_sp25/11670434.html . Accessed April 25, 2014
• 5 Finan E, Sehgal A, McNamara P. Targeted Neonatal Echocardiography in Canada; Need for Standardised Training and Quality Assurance. In: Pediatric Academic Societies Annual Meeting. Denver, Colorado. 30 April-3 May 2011; abstract 3832.306. Available at: http://www.abstracts2view.com/pasall/ . Accessed April 25, 2014
• 6 Evans N, Gournay V, Cabanas F , et al. Point-of-care ultrasound in the neonatal intensive care unit: international perspectives. Semin Fetal Neonatal Med 2011; 16 (1) 61-68
• 7 Isayama T, Lee SK, Mori R , et al; Canadian Neonatal Network; Neonatal Research Network of Japan. Comparison of mortality and morbidity of very low birth weight infants between Canada and Japan. Pediatrics 2012; 130 (4) e957-e965
• 8 Ministry of Health Labour and Welfare in Japan. e-Stat (Vital Statistics, Birth Tables) [in Japanese]. Available at: http://www.e-stat.go.jp/SG1/estat/OtherList.do?bid=000001041645&cycode=7 . Accessed December 18, 2014
• 9 Statistics Canada. CANSIM, Live births, by birth weight and sex, Canada, provinces and territories (Table 102–4509). Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1024509 . Accessed December 18, 2014
• 10 Kramer MS, Platt RW, Wen SW , et al; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108 (2) E35
• 11 Uehara R, Miura F, Itabashi K, Fujimura M, Nakamura Y. Distribution of birth weight for gestational age in Japanese infants delivered by cesarean section. J Epidemiol 2011; 21 (3) 217-222
• 12 Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994; 30 (5) 406-411
• 13 Kluckow M, Seri I, Evans N. Functional echocardiography: an emerging clinical tool for the neonatologist. J Pediatr 2007; 150 (2) 125-130
• 14 Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995; 127 (5) 774-779
• 15 O'Rourke DJ, El-Khuffash A, Moody C, Walsh K, Molloy EJ. Patent ductus arteriosus evaluation by serial echocardiography in preterm infants. Acta Paediatr 2008; 97 (5) 574-578
• 16 Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2014; 99 (2) F99-F104
• 17 Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996; 128 (5 Pt 1) 601-607
• 18 Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001; 6 (1) 63-73
• 19 Su BH, Peng CT, Tsai CH. Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 1999; 81 (3) F197-F200
• 20 McCurnin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics 2008; 122 (6) e1262-e1267
• 21 Firth J, Pickering D. Timing of indomethacin therapy in persistent ductus. Lancet 1980; 2 (8186) 144
• 22 Mirea L, Sankaran K, Seshia M , et al; Canadian Neonatal Network. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161 (4) 689-94.e1
• 23 Loepke AW. Developmental neurotoxicity of sedatives and anesthetics: a concern for neonatal and pediatric critical care medicine?. Pediatr Crit Care Med 2010; 11 (2) 217-226
• 24 Jain A, Sahni M, El-Khuffash A, Khadawardi E, Sehgal A, McNamara PJ. Use of targeted neonatal echocardiography to prevent postoperative cardiorespiratory instability after patent ductus arteriosus ligation. J Pediatr 2012; 160 (4) 584-589.e1
• 25 Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005; 88 (3) 192-201
• 26 Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 1995; 346 (8988) 1464-1465
• 27 Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996; 75 (3) F183-F186
• 28 Schmidt B, Roberts RS, Fanaroff A , et al; TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006; 148 (6) 730-734
• 29 Edwards AD, Wyatt JS, Richardson C , et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 1990; 335 (8704) 1491-1495
• 30 Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A ; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150 (3) 229-234 , 234.e1